- Home
- ISPR vs CRVS Comparison
ISPR vs CRVS Comparison
Compare ISPR & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISPR
- CRVS
- Stock Information
- Founded
- ISPR 2019
- CRVS 2014
- Country
- ISPR United States
- CRVS United States
- Employees
- ISPR N/A
- CRVS N/A
- Industry
- ISPR Medicinal Chemicals and Botanical Products
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- ISPR Health Care
- CRVS Health Care
- Exchange
- ISPR Nasdaq
- CRVS Nasdaq
- Market Cap
- ISPR 170.1M
- CRVS 206.5M
- IPO Year
- ISPR 2023
- CRVS 2016
- Fundamental
- Price
- ISPR $2.90
- CRVS $3.35
- Analyst Decision
- ISPR Strong Buy
- CRVS Strong Buy
- Analyst Count
- ISPR 2
- CRVS 3
- Target Price
- ISPR $10.75
- CRVS $15.67
- AVG Volume (30 Days)
- ISPR 37.3K
- CRVS 962.2K
- Earning Date
- ISPR 05-16-2025
- CRVS 05-08-2025
- Dividend Yield
- ISPR N/A
- CRVS N/A
- EPS Growth
- ISPR N/A
- CRVS N/A
- EPS
- ISPR N/A
- CRVS N/A
- Revenue
- ISPR $148,524,656.00
- CRVS N/A
- Revenue This Year
- ISPR $6.22
- CRVS N/A
- Revenue Next Year
- ISPR $36.16
- CRVS N/A
- P/E Ratio
- ISPR N/A
- CRVS N/A
- Revenue Growth
- ISPR 5.10
- CRVS N/A
- 52 Week Low
- ISPR $2.50
- CRVS $1.75
- 52 Week High
- ISPR $8.40
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- ISPR 44.55
- CRVS 45.93
- Support Level
- ISPR $2.70
- CRVS $3.17
- Resistance Level
- ISPR $3.00
- CRVS $3.71
- Average True Range (ATR)
- ISPR 0.24
- CRVS 0.20
- MACD
- ISPR 0.02
- CRVS 0.02
- Stochastic Oscillator
- ISPR 31.45
- CRVS 31.75
About ISPR Ispire Technology Inc.
Ispire Technology Inc is engaged in the research and development, design, commercialization, sales, marketing, and distribution of branded e-cigarettes and cannabis vaping products. The company sells its cannabis vaping in the United States, Europe, Canada, and South Africa.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).